Reference : Long-term efficacy and safety of Raltegravir combined with optimized background therapy ...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
http://hdl.handle.net/2268/71239
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials.
English
Steigbigel, Roy T [> > > >]
Cooper, David A [> > > >]
Teppler, Hedy [> > > >]
Eron, Joseph J [> > > >]
Gatell, Jose M [> > > >]
Kumar, Princy N [> > > >]
Rockstroh, Jurgen K [> > > >]
Schechter, Mauro [> > > >]
Katlama, Christine [> > > >]
Markowitz, Martin [> > > >]
Yeni, Patrick [> > > >]
Loutfy, Mona R [> > > >]
Lazzarin, Adriano [> > > >]
Lennox, Jeffrey L [> > > >]
Clotet, Bonaventura [> > > >]
Zhao, Jing [> > > >]
Wan, Hong [> > > >]
Rhodes, Rand R [> > > >]
Strohmaier, Kim M [> > > >]
Barnard, Richard J [> > > >]
Isaacs, Robin D [> > > >]
Nguyen, Bach*-Yen T [> > > >]
Moutschen, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén. >]
2010
Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
Univ Chicago Press
50
4
605-12
Yes (verified by ORBi)
International
1058-4838
1537-6591
Chicago
IL
[en] BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
http://hdl.handle.net/2268/71239
10.1086/650002

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
steigbigel.pdfPublisher postprint340.32 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.